Search research articles
Contact Us
Filters
Showing results (101-110 of 129) with videos related to
Page
of 13
Sort By:
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
The New England Journal of Medicine
|
June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty, Caroline Robert, Peter Hersey, et al.
The Lancet. Oncology
|
February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Janet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Health Technology Assessment (Winchester, England)
|
September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
Fiona Collinson, Kara-Louise Royle, Jayne Swain, et al.
Canadian Journal of Kidney Health and Disease
|
November 3, 2022
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors: Description of Clinical Research Protocol of the KINDEST-CCS Study
Adree Khondker, Michael Groff, Sophia Nunes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Nature Medicine
|
May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Claus Garbe, Reinhard Dummer, Teresa Amaral, et al.
Contemporary Clinical Trials Communications
|
November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 129) with videos related to
Sort By:
Page
of 13
Contemporary Clinical Trials
|
September 20, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
Bhavna Oza, Eleni Frangou, Ben Smith, et al.
The New England Journal of Medicine
|
June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
Keith T Flaherty, Caroline Robert, Peter Hersey, et al.
The Lancet. Oncology
|
February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Janet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Health Technology Assessment (Winchester, England)
|
September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
Fiona Collinson, Kara-Louise Royle, Jayne Swain, et al.
Canadian Journal of Kidney Health and Disease
|
November 3, 2022
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors: Description of Clinical Research Protocol of the KINDEST-CCS Study
Adree Khondker, Michael Groff, Sophia Nunes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Nature Medicine
|
May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Claus Garbe, Reinhard Dummer, Teresa Amaral, et al.
Contemporary Clinical Trials Communications
|
November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Page
of 13